Portal de Periódicos da CAPES

Survival from breast cancer in women with a BRCA2 mutation by treatment

2021; Springer Nature; Volume: 124; Issue: 9 Linguagem: Inglês

10.1038/s41416-020-01164-1

1532-1827

D. Gareth Evans, Kelly‐Anne Phillips, Roger L. Milne, Robert Fruscio, Cezary Cybulski, Jacek Gronwald, Jan Lubiński, Tomasz Huzarski, Zerin Hyder, Claire Forde, Kelly Metcalfe, Leigha Senter, Jeffrey N. Weitzel, Nadine Tung, Dana Zakalik, Maria Ekholm, Ping Sun, Steven A. Narod, Maria Błasińska-Morawiec, Maria Chosia, Kazimierz Drosik, S. Gozdecka-Grodecka, Stanisław Góźdż, Ewa Grzybowska, Arkadiusz Jeziorski, Aldona Karczewska, Radzisław Kordek, Agnieszka Synowiec, Beata Kozak‐Klonowska, Katarzyna Lamperska, Dariusz Lange, Andrzej Maćkiewicz, Jerzy Mituś, Stanislas Niepsuj, Oleg Oszurek, K Gugała, Zbigniew Morawiec, Tomasz Mierzwa, Michał Posmyk, Janusz Ryś, Cezary Szczylik, Michał Uciński, Krzysztof Urbański, Bernard Waśko, Piotr Wandzel, Michael Friedlander, Sue Anne McLachlan, Stephanie Nesci, Sandra Picken, Sarah O’Connor, Lucy Stanhope, Andrea Eisen, Kevin Sweet, Raymond H. Kim, William D. Foulkes, Pål Møller, Susan L. Neuhausen, Carey A. Cullinane, Charis Eng, Peter Ainsworth, Fergus Couch, Christian F. Singer, Beth Y. Karlan, Wendy McKinnon, Marie Wood,

Breast Cancer Treatment Studies

The impact of various breast-cancer treatments on patients with a BRCA2 mutation has not been studied. We sought to estimate the impact of bilateral oophorectomy and other treatments on breast cancer-specific survival among patients with a germline BRCA2 mutation. We identified 664 women with stage I–III breast cancer and a BRCA2 mutation by combining five different datasets (retrospective and prospective). Subjects were followed for 7.2 years from diagnosis to death from breast cancer. Tumour characteristics and cancer treatments were patient-reported and derived from medical records. Predictors of survival were determined using Cox proportional hazard models, adjusted for other treatments and for prognostic features. The 10-year breast-cancer survival for ER-positive patients was 78.9% and for ER-negative patients was 82.3% (adjusted HR = 1.23 (95% CI, 0.62–2.45, p = 0.55)). The 10-year breast-cancer survival for women who had a bilateral oophorectomy was 89.1% and for women who did not have an oophorectomy was 59.0% (adjusted HR = 0.45; 95% CI, 0.28–0.72, p = 0.001). The adjusted hazard ratio for chemotherapy was 0.83 (95% CI, 0.65–1.53: p = 0.56). For women with breast cancer and a germline BRCA2 mutation, positive ER status does not predict superior survival. Oophorectomy is associated with a reduced risk of death from breast cancer and should be considered in the treatment plan.